Differential COVID-19-attributable mortality and BCG vaccine use in countries
Preprint
Abstract
While mortality attributable to COVID-19 has devastated global health systems and economies, striking regional differences have been observed. The Bacille Calmette Guérin (BCG) vaccine has previously been shown to have non-specific protective effects on infections, as well as long-term efficacy against tuberculosis. Using publicly available data we built a simple log-linear regression model to assess the association of BCG use and COVID-19-attributable mortality per 1 million population after adjusting for confounders including country economic status (GDP per capita), and proportion of elderly among the population. The timing of country entry into the pandemic epidemiological trajectory was aligned by plotting time since the 100 th reported case. Countries with economies classified as lower-middle-income, upper-middle-income and high-income countries (LMIC, UMIC, HIC) had median crude COVID-19 log-mortality of 0.4 (Interquartile Range (IQR) 0.1, 0.4), 0.7 (IQR 0.2, 2.2) and 5.5 (IQR 1.6, 13.9), respectively. COVID-19-attributable mortality among BCG-using countries was 5.8 times lower [95% CI 1.8-19.0] than in non BCG-using countries. Notwithstanding limitations due to testing constraints in LMICs, case ascertainment bias and a plausible rise of cases as countries progress along the epidemiological trajectory, these analyses provide intriguing observations that urgently warrant mobilization of resources for prospective randomized interventional studies and institution of systematic disease surveillance, particularly in LMICs.Keywords
This publication has 24 references indexed in Scilit:
- An interactive web-based dashboard to track COVID-19 in real timeThe Lancet Infectious Diseases, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in ItalyJAMA, 2020
- Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, ChinaJAMA, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Non-specific effects of BCG vaccine on viral infectionsClinical Microbiology and Infection, 2019
- BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained ImmunityCell Host & Microbe, 2018
- Nonspecific Effects of Vaccines and the Reduction of Mortality in ChildrenClinical Therapeutics, 2013
- Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytesProceedings of the National Academy of Sciences, 2012
- Long-term Efficacy of BCG Vaccine in American Indians and Alaska NativesJAMA, 2004